Rajat Bannerji MD PhD
Hematologic Oncology
Professor, Medicine, Rutgers Robert Wood Johnson Medical School
Join to View Full Profile
195 Little Albany StNew Brunswick, NJ 08901
Phone+1 732-235-7996
Fax+1 732-448-7894
Dr. Bannerji is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1998 - 2001
Johns Hopkins UniversityResidency, Internal Medicine, 1995 - 1998
Weill Cornell MedicineClass of 1995
Certifications & Licensure
NJ State Medical License 2006 - 2025
NY State Medical License 2006 - 2008
PA State Medical License 1998 - 2008
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2014 Jan 15
- Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2020 May 06
Publications & Presentations
PubMed
- 2 citationsPolatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.Sam Yuen, Tycel J Phillips, Rajat Bannerji, Paula Marlton, Giuseppe Gritti
American Journal of Hematology. 2024-07-01 - 37 citationsConsensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji
Blood. 2024-04-18 - 7 citationsMolecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relap...Jurriaan Brouwer-Visser, Nathalie Fiaschi, Raquel P Deering, Kamil J Cygan, Darius Scott
Journal for Immunotherapy of Cancer. 2024-03-21
Abstracts/Posters
- Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel TherapiesRajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel TherapiesRajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center StudyRajat Bannerji, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
FDA Pushes Pause on 2 Regeneron Lymphoma Trials for Cytokine Release SyndromeDecember 15th, 2020- Durable Responses Seen with Odronextamab in Refractory B-cell NHLsDecember 7th, 2020
REGN1979 Shows Good Activity in Pretreated Aggressive B-NHLJanuary 15th, 2020- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
